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The polyglandular autoimmune syndrome type I is a rare hereditary autosomal recessive
disease. We describe a child with the classic triad of the disease and her sister with pure
red cell aplasia and cerebellar hypoplasia. The latter received two haematopoietic stem
cell transplantations, complicated by an acute disseminated encephalomyelitis.
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INTRODUCTION
The polyglandular autoimmune syndrome type I (APS-1), also known as autoimmune
polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), is a rare hereditary autosomal
recessive disease characterized by the classic triad of adrenal insufficiency (Addison’s disease),
hypoparathyroidism, and chronic mucocutaneous candidiasis. The disease may be associated with
other autoimmune disorders such as hypogonadism, type I diabetes mellitus, panhypopituitarism,
pernicious anemia, chronic active hepatitis, pancreatitis, pneumonitis, nephritis, malabsorption
syndrome, vitiligo, alopecia, enamel dysplasia, nail dystrophy, retinitis, keratopathy, and pure red
cell aplasia (1, 2). The disease is caused by mutations in the autoimmune regulator gene AIRE
(3, 4). This gene was mapped at 22q22.3 and consisted of 14 exons (4). More than 100 different
mutations have been reported (2). The prevalence is ∼1:100,000 with a higher prevalence in
some countries, such as Finland (1:25,000) (2). Autoimmune pathogenesis is supported by the
detection of organ-specific autoantibodies and autoantibodies to type 1 interferons (interferon-
α and interferon-ω) (5, 6). The absence of autoantibodies does not rule out the presence of
a specific organ antibody-mediated damage, as autoantibodies may disappear once the target
organ has been completely destroyed (7). Association between APS-1 and pure red cell aplasia
(PRCA) is rare: only 8 cases have been described in the literature (8–14). We describe two
Caucasian sisters with the same AIRE mutation, but different phenotypic expression of APS-1.
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The older sister has the classic triad with adrenal insufficiency,
hypoparathyroidism, and chronic mucocutaneous candidiasis
while the younger one has a partial adrenal failure associated with
PRCA and mild cerebellar hypoplasia; the latter received two
haematopoietic stem cell transplantations, both complicated by
graft failure. The occurrence of autoimmune demyelinating
encephalitis after the second haematopoietic stem cell
transplantation (HSCT) is also described.
CASE REPORT
Case 1
An 8 year-old Ukrainian female, sister of case 2, was referred
to our Emergency Department for fever, vomit, and abdominal
pain while she was in Italy together with her parents, who were
assisting her sister for allogeneic HSCT. The patient was born
after a full-term gestation, from non-consanguineous parents,
the birth weight being 3,000 grams. The patient first presented
chronic nail candidiasis when she was 2 year old, followed by
oral candidiasis at 3. At the age of 5, she developed seizures
that were treated with anticonvulsant therapy (levetiracetam
and lamotrigine). When she was 6 years old, primary adrenal
failure was diagnosed and hydrocortisone replacement therapy
was started. Growth retardation was reported from the age
of 6. Physical examination when the child came to our
attention: weight 16.7 Kg (<3◦p), height 115 cm (−2 DS), painful
abdomen, and oral-nail candidiasis (Figure 1A). Blood exams
showed a slight increase of white blood cells (WBC) and
inflammatory indices [WBC 17.320/mm3, polymorphonuclear
cells (PMN) 14.350/mm3, C-reactive protein (CRP) 29 mg/dL]
associated with severe hyponatremia and hypocalcemia (Na 112
mmol/L, Ca 1.64 mmol/L). Parathormon (PTH) resulted <
0.26 pmol/L (nv 1.00–8.00). Hydrocortisone and fludrocortisone
were administered intravenously at first and a slow intravenous
correction of electrolytes was started. The association of
chronic mucocutaneous candidiasis, adrenal insufficiency and
hypoparathyroidism led to the diagnosis of APS-1 which was
confirmed by AIRE mutation: homozygous mutation in exon
6: c.769C>T (p.Arg257∗). An extended diagnostic assessment
was performed to rule out any possible associated manifestation.
Eye examination revealed bilateral autoimmune keratitis and
dental evaluation showed enamel hypoplasia (amelogenesis
imperfecta) (Figure 1B). The reported seizures were most
likely secondary to hyponatremia and hypocalcemia. For
this reason, an electroencephalography (EEG) was performed,
showing no abnormalities. Hydrocortisone was adapted to
sodium levels. Treatment also included supplementation with
calcitriol and calcium for hypoparathyroidism and antimycotic
therapy with fluconazole for chronic mucocutaneous candidiasis.
Currently the child is in good clinical condition with normal
blood tests.
Case 2
The 6 year-old younger sister was referred to our center from
Ukraine in order to perform HSCT for PRCA, diagnosed at
the age of 3. The patient was born after a full-term gestation.
The birth weight was 3,300 grams. At the age of 3 the
patient was hospitalized for severe paleness and an isolated
normochromic normocytic anemia was detected [hemoglobin 5
g/dl, mean corpuscular volume (MCV) 85 fL (normal value 75.0–
85.0), mean corpuscular hemoglobin (MCH) 29.0 pg (normal
value 25.0–35.0), reticulocytes 1.1%, WBC 11.400/mm3, PMN
5.800/mm3, platelets count 163.000/mm3]. The immunocytology
study of peripheral blood lymphocyte subpopulations showed
a slight increase in the content of T-lymphocytes with a
normal CD4 +/CD8 + ratio, and a moderate decrease (as
a percentage and as absolute value) of natural killer cells.
Physical examination was normal. Bone marrow aspirate and
biopsy showed complete absence of erythroid lineage, normal
granulocyte and megakaryocyte, absence of blast cells and
signs of myelodysplastic syndrome (Figure 1C). Bone marrow
cytogenetics (fluorescent in situ hybridization): negative for
trisomy 8, trisomy 21, monosomy 5 or deletion of long arm
of chromosome 5 (−5 q). No monosomy 7 nor deletion of
long arm of chromosome 7 (−7 q), and no disorder of the sex
chromosomes were identified. An extensive diagnostic work-
up excluded other common causes of anemia: Diepoxybutane
test for Fanconi anemia, the detection of paroxysmal nocturnal
haemoglobinuria (PNH) clone, the Adenosine Deaminase
enzyme activity and the study of genetic mutations for Diamond-
Blackfan anemia resulted negative or normal. Moreover, an
autoimmune lymphoproliferative syndrome was excluded by the
search of double negative T lymphocytes that resulted normal:
0.9% (nv < 1.7%). The culture of haematopoietic progenitor cells
in Colony Forming Unit (CFU) assays showed a cell growth
under the normal range. Serological test did not revealed any
evidence of recent parvovirus B19, cytomegalovirus, Human
herpesvirus 6, Human immunodeficiency virus, hepatitis B
virus, hepatitis C virus, or Epstein-Barr virus infection. Direct
and indirect Coombs’ tests, anti-nuclear antibody, anti-dsDNA,
and Vitamin B12 were normal. The patient received initially
therapy with intravenous immunoglobulin, corticosteroid, and
erythropoietin without efficacy. The patient was treated once
every 7–10 days with red blood cells (RBC) transfusion associated
with chelation therapy. Based on the unresponsiveness to
the therapy and the transfusion dependency, the patient was
candidate for allogeneic HSCT. During pre-transplant work-
up the brain Magnetic Resonance Imaging (MRI) showed a
mild cerebellar hypoplasia (Figure 1D) and routine blood exams
showed severe hyponatremia (sodium 122 mmol/L) that had
never been highlighted before. The presence of hyponatremia
and the recent diagnosis of APS-1 in her sister led to suspect
the same diagnosis in this patient and a search for mutations of
the AIRE gene was launched. Indeed she underwent hormonal
tests that revealed partial adrenal failure (normal basal cortisol
559 nmol/L (normal value 120–620), high basal ACTH 339.28
pg/mL (normal value 8.11–59.53), normal response to ACTH
stimulation test, without hypoparathyroidism nor any other
hormonal alteration. Therefore, therapy with hydrocortisone was
started. Considering the transfusion dependency, the patient
proceeded with the scheduled HSCT from an unrelated bone
marrow donor.
Conditioning regimen was based on treosulfan (3 × 12
g/m2/day), fludarabine (5 × 30 mg/m2/day), thiotepa (2 ×
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FIGURE 1 | Nails and teeth of patient 1. Bone marrow aspirate and brain MRI of patient 2. (A) Nail dystrophy with candidiasis and (B) enamel hypoplasia
(amelogenesis imperfecta) in patient 1. (C) May-Grunwald-Giemsa-stained bone marrow smear (×40 magnification) showing the absence of erytrhoid precursors with
normal component of myeloid precursors and lymphocytes and (D) MRI that shows mild hemispheric and vermian cerebellar hypoplasia in patient 2.
5 mg/kg), and rabbit antithymocyte globulin (ATG NeoviiTM)
(3 × 13 mg/kg/day). The composition of the graft was:
total nucleated cell (TNC) 5.66 × 108/kg and CD34+ 5.55
× 106/kg. Graft vs. host disease (GVHD) prophylaxis was
based on cyclosporine and short term methotrexate. The result
of AIRE mutation arrived during the first month of HSCT,
confirming that the girl presented the same AIRE mutation
as her sister (homozygous mutation in exon 6: c.769C>T
(p.Arg257∗). Meanwhile, after a transient increase of neutrophil
count on day + 19 (peak neutrophil count of 6.920/mm3), the
patient presented a progressive decrease of neutrophil count
and the chimerism analysis performed on day + 26 confirmed
the graft failure (0% donor-derived cells). Given the patient
good clinical conditions, a second transplant from the same
unrelated donor was scheduled 42 days after the first transplant.
Considering the complete bone marrow aplasia, a reduced
intensity conditioning regimen, similar to that recommended for
severe aplastic anemia, was used: rabbit antithymocyte globulin
(ATG GenzymeTM) (3 × 3.3 mg/kg/day), cyclophosphamide
(4 × 30 mg/kg/day), fludarabine (4 × 30 mg/ m2/day), while
GVHD prophylaxis was based on cyclosporine and short term
methotrexate. The graft cell dose was: TNC 5.82 × 108/kg and
CD34+ 2.62 × 106/kg. On day +5 the child presented sub-
acute onset of headache, lethargy, confusion, slurred speech, and
left-hemibody hyposthenia. The electroencephalogram (EEG)
showed a continuous ictal epileptic discharge involving the right
hemisphere (Figure 2A), consistent with the diagnosis of focal
status epilepticus (SE), successfully treated with intravenous
administration of levetiracetam and phenytoin. Once SE was
controlled, a residual confusional state was observed with
EEG, showing an encephalopathic pattern characterized by
diffuse slowing clearly predominant on the right hemisphere
and periodic temporo-occipital sharp transients (Figure 2B).
Brain MRI showed multiple focal hyperintense lesions in T2-
weighted (Figures 2E–H) and FLAIR (Figures 2I–P) sequences,
localized in corpus callosum (Figures 2E–P), right posterior
thalamus (Figures 2I,M) and at the cortico-subcortical junction
bilaterally(Figures 2J,O), mainly on the right hemisphere. The
cerebrospinal fluid (CSF) findings showed elevated protein
concentration while it resulted negative for bacterial and
viral infections. Serum and CSF analysis resulted negative for
anti-glutamic acid decarboxylase antibodies (anti-GAD), anti-
NMDAR, anti-AMPA1, anti-AMPA2, anti-CASPR2, anti-LGI1,
anti-GABARB1/B2, anti-myelin oligodendrocyte glycoprotein
antibodies (anti-MOG), while the presence of oligoclonal bands
was detect only in CSF. The patient was treated with intravenous
immunoglobulins (2 g/kg) with gradual clinical improvement
in 3 days and complete resolution of symptoms within a week.
The EEG performed after 10 days from onset demonstrated
a slight inter-hemispheric asymmetry, due to excessive slow
activities on the right posterior regions (Figure 2C). A follow-
up MRI performed 30 days after the encephalitic episode showed
a complete resolution of the focal lesions (Figures 2Q–T). After
a primary myeloid engraftment on day +13 (peak neutrophil
count of 5.400/mm3), the patient had another early secondary
graft failure on day +30 (0% donor-derived cells). Despite that,
since day +30 the girl had a progressive recovery of blood
values and she no longer needed transfusions, maintaining a
normal blood count on erythropoietin treatment. A bonemarrow
aspirate performed 100 days after the second transplant showed a
normal trilineage haematopoiesis with the presence of erythroid
precursors (Figure 3), whereas the chimerism confirmed a
complete recipient reconstitution (0% donor-derived cells). The
EEG performed 3 months after encephalitis showed a complete
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FIGURE 2 | EEG and MRI evolution of encephalitic episode. (A–D) EEG recordings in longitudinal bipolar montage, 15 s each panel, calibration (MKR) amplitude 100
µV. In (A) a clear-cut ongoing epileptic discharge involving the right hemisphere (mainly the infrasylvian derivations) is documented, clinically associated with the
sub-acute onset of neurological symptoms, consistent with the diagnosis of focal Non-Convulsive Status Epilepticus (NCSE). In (B) the recording obtained 8 h later,
after intravenous levetiracetam and phenytoin treatment, shows the resolution of the NCSE with residual diffuse slowing (predominant on the right hemisphere)
(Continued)
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FIGURE 2 | and periodic temporo-occipital sharp transients (more evident on P4-O2, T4-T6, and T6-O2 channels). Ten days after sub-acute onset, the EEG does not
show epileptiform discharges, but an increased amount of slow activity remains, with obvious preponderance on the right temporal regions (C). In (D) the EEG
recording performed after 3 months demonstrates a complete recovery, with normal reactivity of the posterior background alpha rhythm. (E–P): Brain MRI images
obtained at the onset of neurological symptoms, demonstrating multiple focal hyperintense lesions in T2-weighted (sagittal plane in E; axial images in F–H) and FLAIR
(axial images I–L; coronal plane in M–P) sequences. The largest 3 lesions were located in corpus callosum (arrows in E–H,J–L,N–P). A clear hyperintensity was also
visible on the right posterior thalamus (circles in I,M). Multiple lesions were evident at the cortico-subcortical junction bilaterally (arrowheads in J,O), mainly involving
the right hemisphere, being the largest in the right temporo-occipital region (O). The MRI performed 30 days after the encephalitic episode showed a complete
resolution of the focal lesions (in panels Q–T are depicted the correspondent coronal FLAIR images as in M–P).
FIGURE 3 | Bone marrow aspirate at 100 days after the second transplant.
May-Grunwald-Giemsa-stained bone marrow smear (×100 magnification)
showing normal trilineage haematopoiesis with the presence of erythroid
precursors.
normalization of previous pathological findings (Figure 2D). At
her last follow-up visit on day +150 after the second transplant,
the child is in excellent general condition (Lansky play score
100%) with a normal blood count and transfusion-independency
although supported with erythropoietin (10,000 UI once
every 2 weeks).
DISCUSSION
APS-1 is characterized by a marked clinical variability. The risk
to develop organ-specific autoimmune manifestations depends
upon both environmental factors and genetic susceptibility (2).
We described two sisters with the same AIRE mutation but
different phenotypes. The older girl (case 1) presented a classic
pattern of the disease, including the three cardinal characteristics:
chronic mucocutaneous candidiasis, hypoparathyroidism, and
adrenal insufficiency. The younger girl presented some atypical
features of the disease like PCRA and cerebellar hypoplasia.
PRCA is characterized by normocytic anemia, reticulocytopenia,
absence of erythroid precursors in the bone marrow with
normal values of white blood cells and platelets. It can be
considered as the result of antibody-mediated or T-cell-mediated
damage of the erythroid progenitor cell with an inhibition
of erythropoiesis (9). The role of γδ T-cell receptor positive
lymphocytes in the pathogenesis of the PRCA associated with
APS-1 is described in several papers (9, 10). Only 8 cases
of PRCA associated with APS-1 have been reported in the
literature. In most cases the onset of PRCA occurs during the
course of the disease, in adulthood, after the development of
the typical manifestations of the APS-1 (8–12). In literature
only 3 children with PRCA and APS-1 have been reported.
In one of the cases [a 10 year-old girl (13)] PRCA developed
after the onset of the typical characteristics of APS-1; in the
other described cases (a 7 year-old and a 15 year-old patient)
PRCA was the prominent feature of the APS-1 (14). In our
case as well PRCA was the main manifestation of the disease
and began before adrenal insufficiency. The diagnosis of PRCA
was made at the age of 3: this is the earliest onset age
reported in the literature. The therapy of PRCA associated
with APS-1 is currently not standardized due to the rarity
of the disease. In the cases reported in the literature the
therapy that was used with good results was corticosteroid (12–
14), cyclophosphamide (11–13), mycophenolate mofetil (10),
plasmapheresis (13), immunoglobulin (8, 13, 14), cyclosporine
(8), antithymocyte globulin (ATG) (8). In our patient, no benefit
was obtained by treatment with immunoglobulin, corticosteroid,
and erythropoietin therapy. The child became transfusion-
dependent and was referred to receive an HSCT. She represents
the first case of PRCA associated with APS-1 undergoing
HSCT. In literature there are no reported cases of APS-1
with cerebellar hypoplasia, but it is described in association
with hereditary bone marrow failure like Fanconi anemia (15),
dyskeratosis congenital (16), Diamond-Blackfan anemia (17),
congenital amegakaryocytic thrombocytopenia (18), or ataxia-
pancytopenia syndrome (19). Some cases of patients with
cerebellitis and APS-1 are described (20); in these patients high
serum and CSF titers of anti-GAD were found, with intrathecal
production of such antibodies. In our patient serum and CSF
analysis were performed after the transplantation, when the
child developed an encephalitis, and they resulted negative for
all autoantibodies against neuronal surface and intracellular
antigens but positive for oligoclonal bands in CSF. This finding
probably suggests an immune-mediated pathogenesis of the
damage which developed after HSCT, as described in some
other papers (21–23). Neurologic complications after HSCT
are relatively common, but demyelinating disease is rare (23).
The features of MRI lesions are highly suggestive of an acute
disseminated encephalomyelitis (ADEM). In our case the onset
of neurological symptoms is very close to the II HSCT so we
suppose that the damage is a consequence of the I HSCT. In
literature, the reported mean time from HSCT to the beginning
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of symptoms of ADEM is about 120 days (23); in our case the
symptoms appeared 47 days after the first HSCT and 5 days
after the second one. Therapy with immunoglobulin was shown
to be effective with prompt clinical response and disappearance
of MRI lesions, as already reported (21–24). The child is
currently in clinical and hematological remission of disease,
transfusion-indipendent with normal blood count despite graft
failure occurred twice as documented by the complete patient
myeloid recovery at chimerism analysis. Given the fact that
hematological remission have been described in patients with
PRCA associated with APS-1 treated with cyclophosphamide (11,
12), we hypothesize that the recovery of erithropoiesis observed
after the second HSCT was the immunosuppressive effect of
cyclophosphamide, included in the conditioning regimen. In
conclusion, we found out that APS-1 has a significant clinical
heterogeneity despite the same genetic mutation and this has
to be considered in the differential diagnosis of pure red cell
aplasia. In our experience, this condition might be treated with
a therapeutic regimen that includes the use of the ATG and the
cyclophosphamide as severe aplastic anemia, while the HSCT
is characterized by a high risk of graft failure. Finally, our case
showed the efficacy of immunoglobulin therapy in a case of
ADEM post HSCT.
DATA AVAILABILITY
The datasets generated for this study can be found in U.O
servizio di anatomia patologica, Università degli Studi di
Brescia, GM2018-000457.
ETHICS STATEMENT
Written informed consent was obtained from patients’ parents
for publication of this case report and any potentially-
identifying information/images. The work was exempt from
ethics committee review/approval.
AUTHOR CONTRIBUTIONS
MC involvement in medical diagnosis and follow up of patients,
first writer of the manuscript. MM and GC involvement
in medical diagnosis of patients, they helped to write the
manuscript. RB, MD, VV, AZ, EB, RG, and EF involvement
in diagnosis and management of patients. SC involvement
in diagnosis and management of patients, supervision of the
process of the manuscript. All authors read and approved the
final manuscript.
REFERENCES
1. Husebye ES, Perheentupa J, Rautemaa R, Kämpe O. Clinical manifestations
and management of patients with autoimmune polyendocrine syndrome type
I. J Intern Med. (2009) 265:514–29. doi: 10.1111/j.1365-2796.2009.02090.x
2. Husebye ES, Anderson MS, Kämpe O. Autoimmune polyendocrine
syndromes. N Engl J Med. (2018) 378:1132–41. doi: 10.1056/NEJMra17
13301
3. Finnish-German APECED Consortium. An autoimmune disease, APECED,
caused by mutations in a novel gene featuring two PHD-type zinc-finger
domains. Nat Genet. (1997) 17:399–403. doi: 10.1038/ng1297-399
4. Nagamine K, Peterson P, Scott HS, Kudoh J, Minoshima S, Heino M,
et al. Positional cloning of the APECED gene. Nat Genet. (1997) 17:393–8.
doi: 10.1038/ng1297-393
5. Meager A, Visvalingam K, Peterson P, Möll K, Murumägi A,
Krohn K, et al. Anti-interferon autoantibodies in autoimmune
polyendocrinopathy syndrome type 1. PLoS Med. (2006) 3:e289.
doi: 10.1371/journal.pmed.0030289
6. Dalin F, Nordling Eriksson G, Dahlqvist P, Hallgren Å, Wahlberg J, Ekwall
O, et al. Clinical and immunological characteristics of autoimmune addison
disease: a nationwide swedish multicenter study. J Clin Endocrinol Metab.
(2017) 102:379–89. doi: 10.1210/jc.2016-2522
7. Maung ZT, Norden J, Middleton PG, Jack FR, Chandler JE. Pure red cell
aplasia: further evidence of T cell clonal disorder. Br J Haematol. (1994)
87:189–9. doi: 10.1111/j.1365-2141.1994.tb04890.x
8. Grossi A, Nozzoli C, Gheri R, Santini V, Marrani C, Zoccolante A, et al.
Pure red cell aplasia in autoimmune polyglandular syndrome with T
lymphocytosis. Haematologica (1998) 83:1043–5.
9. Hara T, Mizuno Y, Nagata M, Okabe Y, Taniguchi S, Harada M, et al.
Human gamma delta T-cell receptor-positive cell-mediated inhibition of
erythropoiesis in vitro in a patient with type I autoimmune polyglandular
syndrome and pure red blood cell aplasia. Blood (1990) 75:941–50.
10. Bakrac M, Jurisic V, Kostic T, Popovic V, Pekic S, Kraguljac N, et al.
Pure red cell aplasia associated with type I autoimmune polyglandular
syndrome-successful response to treatment with mycophenolate mofetil:
case report and review of literature. J Clin Pathol. (2007) 60:717–20.
doi: 10.1136/jcp.2006.042671
11. Orlova EM, Kareva MA, Melikyan MA, Boyakova E, Peterkova VA,
Maschan AA. Response of pure red cell aplasia to cyclophosphamide
after failure of mycofenolate mofetil in a patient with polyglandular
syndrome type I. J Pediatr Hematol Oncol. (2013) 35:e338-40.
doi: 10.1097/MPH.0b013e3182755c52
12. Myers TJ, Bower BF, Hild DH. Pure red cell aplasia and the syndrome of
multiple endocrine gland insufficiency. Am J Med Sci. (1980) 280:29–34.
doi: 10.1097/00000441-198007000-00005
13. Etzioni A, Atias D, Pollack S, Levy J, Vardi P, Hazani H, et al. Complete
recovery of pure red cell aplasia by intramuscular gammaglobulin therapy
in a child with hypoparathyroidism. Am J Hematol. (1986) 22:409–14.
doi: 10.1002/ajh.2830220410
14. Mandel M, Etzioni A, Theodor R, Passwell JH. Pure red cell hypoplasia
associated with polyglandular autoimmune syndrome type I. Isr J Med Sci.
(1989) 25:138–41.
15. Stivaros SM, Alston R, Wright NB, Chandler K, Bonney D, Wynn RF, et al.
Central nervous system abnormalities in Fanconi anaemia: patterns and
frequency on magnetic resonance imaging. Br J Radiol. (2015) 88:20150088.
doi: 10.1259/bjr.20150088
16. Olivieri C, Mondino A, Chinello M, Risso A, Finale E, Lanciotti M,
et al. Clinical heterogeneity in a family with DKC1 mutation, dyskeratosis
congenita and Hoyeraal-Hreidarsson syndrome in first cousins. Pediatr Rep.
(2017) 9:7301. doi: 10.4081/pr.2017.7301
17. Alkhunaizi E, Schrewe B, Alizadehfar R, Vézina C, Stewart GS,
Braverman N. Novel 3q27.2-qter deletion in a patient with Diamond-
Blackfan anemia and immunodeficiency: case report and review of
literature. Am J Med Genet A (2017) 173:1514–20. doi: 10.1002/ajmg.a.
38208
18. Eshuis-Peters E, Versluys AB, Stokman MF, van der Crabben SN,
Nij Bijvank SW, van Wezel-Meijler G. Congenital amegakaryocytic
thrombocytopenia type II presenting with multiple central nervous
system anomalies. Neuropediatrics (2016) 47:128–31. doi: 10.1055/s-0036-15
71800
19. Davidsson J, Puschmann A, Tedgård U, Bryder D, Nilsson L, Cammenga
J. SAMD9 and SAMD9L in inherited predisposition to ataxia,
pancytopenia, and myeloid malignancies. Leukemia (2018) 32:1106–15.
doi: 10.1038/s41375-018-0074-4
Frontiers in Pediatrics | www.frontiersin.org 6 February 2019 | Volume 7 | Article 51
Chinello et al. Pure-Red-Cell-Aplasia and Polyglandular-Autoimmune-Syndrome-Type-I
20. Baizabal-Carvallo JF, Alonso-Juarez M. Cerebellar disease associated with
anti-glutamic acid decarboxylase antibodies: review. J Neural Transm. (2017)
124:1171–82. doi: 10.1007/s00702-017-1754-3
21. Stefanou MI, Bischof F. Central and peripheral nervous system
immune-mediated demyelinating disease after allogeneic hematopoietic
stem cell transplantation. J Neuroimmunol. (2017) 307:74–81.
doi: 10.1016/j.jneuroim.2017.04.005
22. Zhang XH, Zhao X,Wang CC, HanW, Chen H, Chen YH, et al. IgG synthesis
rate and anti-myelin oligodendrocyte glycoprotein antibody in CSF may be
associated with the onset of CNS demyelination after haplo-HSCT. Ann
Hematol. (2018) 97:1399–406. doi: 10.1007/s00277-018-3299-4
23. Delios AM, Rosenblum M, Jakubowski AA, DeAngelis LM. Central and
peripheral nervous system immune mediated demyelinating disease after
allogeneic hemopoietic stem cell transplantation for hematologic disease. J
Neurooncol. (2012) 110:251–6. doi: 10.1007/s11060-012-0962-9
24. Dulamea AO, Lupescu IG. Neurological complications of hematopoietic cell
transplantation in children and adults. Neural Regen Res. (2018) 13:945–54.
doi: 10.4103/1673-5374.233431
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2019 Chinello, Mauro, Cantalupo, Balter, De Bortoli, Vitale, Zaccaron,
Bonetti, Gaudino, Fiorini and Cesaro. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use,
distribution or reproduction in other forums is permitted, provided the original
author(s) and the copyright owner(s) are credited and that the original publication
in this journal is cited, in accordance with accepted academic practice. No use,
distribution or reproduction is permitted which does not comply with these terms.
Frontiers in Pediatrics | www.frontiersin.org 7 February 2019 | Volume 7 | Article 51
